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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Endoscopic submucosal dissection has made it possible to resect
large lesions during a single operation. The present study was
undertaken to compare the time taken for recovery from artificial
ulcers after endoscopic submucosal dissection between an H2
Receptor Antagonist treatment group and a Proton Pump Inhibi 
tor treatment group, focusing on analysis of the time course of
reduction rate in ulcer area. The powerful acid suppression by
Proton Pump Inhibitor may not be needed to treat Japanese post 
endoscopic submucosal dissection ulcer which usually develops
after early gastric carcinoma in the mucosa of low acid secretory
capacity. The study involved 60 patients with 69 artificial ulcers
following endoscopic submucosal dissection for the treatment of
tumors remaining in the gastric mucosa. Of all lesions, 36 were
allocated to the H2 Receptor Antagonist group and 33 to the Proton
Pump Inhibitor group. Patients in both groups underwent endo 
scopy at 4 and 8 weeks after the start of administration. There
were no significant differences between two groups and ulcer
healing rates were similar in the two groups. The efficacy of H2
Receptor Antagonists in curing this type of ulcer can thus be
expected to be comparable to that of Proton Pump Inhibitors.
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Introduction Endoscopic therapy for early gastric carcinoma was initiated
in the 1960s and various technologies were developed. Since
the strip biopsy method developed by Tada et al.(1) and the ERHSE
(Endoscopic Resection with local injection of Hypertonic Saline
Epinephrine solution) method developed by Hirao et al.(2) became
available in the 1980s, endoscopic mucosal resection (EMR) for
endoscopic therapy has come into widespread use. Various tech-
niques have also become well-developed but most have focused
on treatment of intra-mucosal lesions of 2 cm or less and therefore
post-EMR ulcers have, like peptic ulcers, been treated with H2
receptor antagonists (H2RA) or proton pump inhibitors (PPI).(3,4)
The insulated tip electrosurgical (IT)-knife(5) developed in 1988
and the approach of Ono et al.(6) in 1999 allowed dissection of
larger lesions exceeding 2 cm; this treatment approach was termed
endoscopic submucosal dissection (ESD). ESD enables larger
specimens to be obtained, resulting in a complete resection rate
of more than 90% compared with conventional EMR methods.
Post-ESD ulcers have been treated with H2RA or PPI like other
post-EMR ulcers. The size of an ulcer artificially induced by endo-
scopic therapies including ESD is generally shallower than a
common peptic ulcer. A meta-analysis found that peptic ulcers are
potentially curable earlier with PPIs than H2RAs due to the
stronger inhibitory action on gastric acid secretion.(7) However,
there is no well-documented report examining whether treatment
of post-ESD ulcers and that of common peptic ulcers should be
same or not.
Most early gastric carcinomas, as indications for endoscopic
therapy, are classified as well-differentiated with severe atrophy in
the background mucosa of the stomach and an inferred decrease in
acid secretory capacity. In addition, it is reported that 70 to 80% of
Japanese were infected with Helicobacter pylori (HP) and that
the acid secretion potential was lower in Japanese people than in
Western populations.(8) Due to the change of dietary habits to
Western-style, the acid secretion in Japanese tends to increase,
but it is still lower than in Western populations.(9) Therefore, the
powerful acid suppression by PPI may not be needed to treat
Japanese post-ESD ulcer which usually develops after early gastric
carcinoma in the mucosa of low acid secretory capacity.
For ulcer healing after EMR, Yamaguchi et al.(3) evaluated the
effectiveness of H2RA and PPI, and concluded that the healing
results were similar for the two drugs. However, whether or not the
treatment for peptic ulcer is also effective for post-ESD ulcer, and
which drugs are suitable for post-ESD ulcers with larger area than
post-EMR ulcers, have not yet been examined.
Therefore, we compared the rate of decrease in ulcer size over
time in patients with post-ESD ulcers treated with H2RA or PPI to
establish a regimen for ESD-induced ulcers assumed to have a
similar depth of ulceration.
Subjects and Methods
Subjects. We conducted ESD for 65 patients with 74 gastric
intra-mucosal tumors between January and June 2009 at the Osaka
Medical College Hospital, Japan. We excluded patients with multi-
organ complications and included 60 patients with 69 gastric
tumors (51 early gastric carcinomas, 18 gastric adenomas) after
giving written informed consent in this study. Subjects were
randomly allocated into two groups (30 in each group) using the
envelop method (Fig. 1).
ESD procedure. The ESD procedure was performed with
the approach of Ono et al.(6) and the actual steps are shown in
Fig. 2. VIO300D (ERBE, Tubingen, Germany) was used as a high-
frequency generator. A needle knife (KD-1L, Olympus Medical
Systems Co. Ltd., Tokyo, Japan)(10) as the marking-tip device was
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used with a coagulation wave (Soft Coag 60W Effect 7) to mark
dots approximately 5 mm outside the margin of the targeted
lesion. Then, the mucosa around the lesion was adequately
inflated by locally injecting 0.05% epinephrine dissolved in saline
into the area between the muscularis propria and the mucosa. The
lesion was pre-cut using the needle knife with the cut wave (Endo
Cut I Effect 2 Duration 3 Interval 3) and incised circumferentially
using an IT-knife 2(11) (KD-611L, Olympus Medical Systems Co.
Ltd.) with the cut wave (Endo Cut Q Effect 2 Duration 4 Interval
3). The submucosal layer under the lesion was dissected using the
same IT knife 2, usually with the coagulation wave (Swift Coag
Effect 2, 60–70W), but occasionally with the cut wave (Endo Cut
Q Effect 2 Duration 4 Interval 3) for the hard-to-dissect fibrous
submucosal layer. The IT-knife 2 with the coagulation wave (Swift
Coag Effect 3, 60–80W) was used to stop oozing blood during the
procedure. In case of inadequate hemostasis, a soft coagulation
wave (Soft Coag Effect 6, 80W) was applied to the bleeding site
pinpointed and clamped with hemostatic forceps (FD-410LR,
Fig. 1. Trial profile. The flow diagram of this study. (PPI group, H2RA group)
Fig. 2. The ESD procedure and hemostasis. a: A IIa gastric tumor with the long axis of 10 mm at anterior pylorus. b: The lesion dyed with indigocar 
mine. c: Marking outer margin of the lesion by a coagulation wave. d: Inflation of the mucosa around the lesion by local injection of solution. e: The
lesion after circumferential incision. f: Dissection of the lesion by IT knife2. g: The lesion during dissection. h: An ulcer floor formed immediately
after ESD. i: Hemostasis of vessels in the ulcer floor.doi: 10.3164/jcbn.11 23
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Olympus Medical Systems Co. Ltd.) to stop bleeding. The hemo-
static forceps were also used for projectile bleeding; in the event of
poor heat transfer of the soft coagulation wave to vessels, another
hemostatic forceps with a larger contact area (Radial Jow 3 HOT
Boston Scientific, Marlborough, Natick Massachusetts) and another
setting for the higher-frequency coagulation wave (Forced Effect
2, 40W) with a coagulation output of approximately 1–2 s were
used to stop the bleeding.
After dissection of the target lesion, all vessels in the floor of
the ulcer were carefully treated using hemostatic forceps and with
the coagulation wave (Soft Coag 80W Effect 6) for prophylaxis
against post-operative hemorrhage.
Bleeding was defined as hematemesis or melena that required
the endoscopic hemostasis and decreased the hemoglobin count by
more than 2 g/dl, occurring from the time of treatment until cure of
ESD-induced ulcer (Fig. 2).
Study protocol design (post ESD treatment). Patients
were not fed for 2 days after ESD procedures and received
roxatidine acetate hydrochloride, an intravenous H2RA given at a
dosage of 150 mg/day during the fasting period. Then, both patient
groups received an anti-ulcer drug orally for 8 weeks; the H2RA
group received roxatidine 150 mg/day and the PPI group received
rabeprazole 10 mg/day. Patients in both groups underwent upper
gastrointestinal endoscopy at 4 and 8 weeks after the start of
administration (Fig. 3).
Measurement of ulcer size. The ESD-induced ulcer size
was assessed by area (mm2); long and short axes (mm) of an
assumed ellipse were measured using an endoscope and mea-
suring equipment and the ulcer size (long radius × short radius ×
π = ulcer size) was calculated (Fig. 4). The indication of EMR is
gastric tumor with long axis less than 20 mm, with the maximum
area = 10 mm radius × 10 mm radius ×π=3 1 4m m 2 of an assumed
circle. The normal mucosa outside the tumor is resected in the
procedure, resulted in ulcers with assumed larger maximum area
with 400 mm2. Therefore, ulcers were classified into two groups,
small ulcers of less than 400 mm2 and large ulcers of at least
400 mm2, using the ulcer size of Day 2 after ESD as the baseline
value.
Ulcer sizes were measured at Weeks 4 and 8 after ESD to
calculate the rate of decrease in ulcer size over time.
Statistical method. Analyses were performed with the SPSS
16.0 software package (SPSS Japan, Tokyo, Japan). Data were
expressed as mean ± standard deviation and tested by chi-square
test or t test. Statistical significance was defined as p<0.05 in a
two-tailed test.
Results
Patient characteristics. The H2RA group (30 patients) and
the PPI group (30 patients) were studied. The H2RA group consisted
of 20 males and 10 females with a mean age of 68.7 ± 9.3 years,
range 49 to 85, whereas the PPI group consisted of 21 males and
9 females with a mean age of 67.4 ± 7.8 years, range 47 to 80.
HP IgG antibody levels in blood were measured (using ELISA kit:
HM-CAP, Kyowa Medex, Tokyo, Japan) and the level of 1.8 U/ml
or above was considered to be HP positive. The HP infection
rate was 76.7% in the H2RA group and 80.0% in the PPI group.
The H2RA group patients had ulcers (36 lesions) in the body (14
lesions), angulus (10) and antrum (12) of the stomach. The PPI
group patients had ulcers (33 lesions) in the body (12 lesions),
angulus (9) and antrum (12) of the stomach. There were no signifi-
cant differences in extraneous factors between the two groups
(Table 1).
Ulcer size after ESD. Ulcer sizes after ESD (baseline value)
were 519.2 ± 436.7 in the H2RA group (36 lesions) and 652.2 ±
514.4 in the PPI group (33 lesions) and there was no significant
difference between the two groups (Table 2).
The rate of decrease in ulcer size. The rates of decrease in
ulcer size were 92.9 ± 9.1% and 99.8 ± 0.7% at Week 4 and Week
8, respectively, in the H2RA group, and 89.0 ± 20.1% and 99.7 ±
1.1% in the PPI group, respectively. There were no significant
differences between the two groups (Table 3).
Ulcers less than 400 mm2. The mean size of 19 ulcers which
were less than 400 mm2 immediately after ESD was 263.6 ±
73.3 mm2 in the H2RA group and the rate of decrease in size was
96.1 ± 6.0% at Week 4 and 100% at Week 8. The mean size of 13
ulcers was 276.4 ± 51.6 mm2 in the PPI group and the rate of
decrease in size was 94.2 ± 5.1% at Week 4 and 99.9 ± 0.2% at
Week 8. There were no significant differences between the two
groups (Table 4).
Ulcers of at least 400 mm2. The mean size of 17 ulcers
exceeding 400 mm2 was 804.8 ± 496.8 mm2 in the H2RA group
and the rate of decrease in size was 89.3 ± 10.7% at Week 4 and
99.7 ± 1.0% at Week 8. The mean size of 20 large ulcers was
896.5 ± 533.4 mm2 in the PPI group and the rate of decrease in
size was 85.6 ± 25.2% at Week 4 and 99.5 ± 1.4% at Week 8.
There were no significant differences between the two groups
(Table 5).
Post ESD complications. There were no patients with post-
ESD bleeding in either group, from the time of treatment until
cure of ESD-induced ulcer.
Fig. 3. Study protocol. Patients were not fed for 2 days after ESD
procedures and received roxatidine acetate hydrochloride, an intra 
venous H2RA given at a dosage of 150 mg/day during the fasting period.
Then, both patient groups received an anti ulcer drug orally for 8
weeks; the H2RA group received roxatidine 150 mg/day and the PPI
group received rabeprazole 10 mg/day. Patients in both groups under 
went upper gastrointestinal endoscopy at 4 and 8 weeks after the start
of administration.
Fig. 4. Measurement of ulcer size. The ESD induced ulcer size was
assessed by area; long and short axes (mm) of an assumed ellipse were
measured using an endoscope and measuring equipment, and the ulcer
size was calculated. J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 219
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Fig. 5. A case treated with H2RA (Roxatidine). a: IIa early gastric cancer at the lesser curvature of gastric angle. b: The lesion was dyed with indigo 
carmine. c: Immediately after ESD, an ulcer floor was formed. d: Two days after ESD, there was white moss in the ulcer floor. e: Four weeks after ESD,
the ulcer floor shrunk and was surrounded by regenerating epithelium. f: Eight weeks after ESD, the ulcer floor disappeared and turned into a scar.
Table 1. Patient characteristics of the treatment groups (H2RA and PPI)
2 sample t test (ns)
The patient characteristics were similar in both groups, and no signifi 
cant differences were observed. H2RA, H2 receptor antagonist; PPI,
proton pump inhibitor.
Variables H2RA PPI
Patients (n) 30 30
Male 20 21
Female 10 9
Age: mean ± SD 68.7 ± 9.3 67.4 ± 7.8
(Range) (49–85) (47–80)
H. pylori positive 23 24
(%) (76.7%) (80.0%)
Lesions (n) 36 33
Site of lesions
Body 14 12
Angle 10 9
Antrum 12 12
Area of ulcer at 0W (mm2) 519.2 ± 436.7 652.2 ± 514.4
Table 2. Ulcer size at baseline (mm2)
mean ± SD
2 sample t test (ns)
Ulcer sizes after ESD (baseline value) were 519.2 ± 436.7 in the H2RA
group (36 lesions) and 652.2 ± 514.4 in the PPI group (33 lesions)
and there was no significant difference between the two groups. ESD,
endoscopic submucosal dissection; H2RA, H2 receptor antagonist; PPI,
proton pump inhibitor.
0 W 95% CI
H2RA (n = 36) 519.2 ± 436.7 (376.5–661.8)
PPI  (n = 33) 652.2 ± 514.4 (476.7–827.7)
Table 3. The rate of decrease in ulcer size (all ulcers)
mean ± SD (95% CI)
2 sample t test (ns)
The rates of decrease in ulcer size were 92.9 ± 9.1% and 99.8 ± 0.7% at
Week 4 and Week 8, respectively, in the H2RA group, and 89.0 ± 20.1%
and 99.7 ± 1.1% in the PPI group, respectively. There were no significant
differences between the two groups. H2RA, H2 receptor antagonist; PPI,
proton pump inhibitor.
Week 4 Week 8
H2RA 92.9 ± 9.1% 99.8 ± 0.7%
(n = 36) (89.9–95.8) (99.6–100)
PPI 89.0 ± 20.1% 99.7 ± 1.1%
(n = 33) (82.1–95.9) (99.3–100)
Table 4. The rate of decrease in ulcer size (ulcers less than 400 mm2)
mean ± SD (95% CI)
2 sample t test (ns)
The mean size of 19 ulcers which were less than 400 mm2 immediately
after ESD was 263.6 ± 73.3 mm2 in the H2RA group and the rate of
decrease in size was 96.1 ± 6.0% at Week 4 and 100% at Week 8. The
mean size of 13 ulcers was 276.4 ± 51.6 mm2 in the PPI group and the
rate of decrease in size was 94.2 ± 5.1% at Week 4 and 99.9 ± 0.2% at
Week 8. There were no significant differences between the two groups.
ESD, endoscopic submucosal dissection; H2RA, H2 receptor antagonist;
PPI, proton pump inhibitor.
Week 4 Week 8
H2RA 96.1 ± 6.0% 100%
(n = 19) (93.4–98.7)
PPI 94.2 ± 5.1% 99.9 ± 0.1%
(n = 13) (91.4–97.0) (99.9–100)doi: 10.3164/jcbn.11 23
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Discussion
ESD is becoming the standard treatment for gastric intra-
mucosal tumors and an effective cure for post-ESD ulcers is
anticipated to be an important future issue. Eriksson et al.(12)
compared H2RA (ranitidine) and PPI (omeprazole) in 743 patients
with gastric ulcers and the outcome as the rates of ulcer healing
at Week 4 and Week 8. The results of the meta-analysis showed
that the PPI group was superior in ulcer healing rate by 9.9% (95%
CI, 3.0–16.8) (p = 0.005) at Week 4 and 6.7% (95% CI, 1.2–12.2)
at Week 8 (p = 0.02). Another meta-analysis by Tunis et al.(7) in
1527 patients involved in 13 studies showed that the rate of ulcer
healing was significantly higher in the PPI group with better
outcomes at both Week 4 (risk ratio = 1.33, 95% CI, 1.19–1.49)
and Week 8 (risk ratio = 1.12, 95% CI, 1.06–1.19) than in the
H2RA group. The depth of these peptic ulcers was varied, ranging
from erosion of level mucosa to ulceration beyond the muscularis
propria, whereas the depth of ESD-induced ulcers remains at
level sub mucosa.
Yamaguchi et al.(3) evaluated the bleeding rate after EMR and
the effects on the healing of post-EMR ulcers of in 57 patients who
were randomly assigned to H2RA or PPI. Neither the bleeding
rates (H2RA 18% versus PPI 14%) nor the size of post-EMR ulcers
at 1, 30, 60 days were significantly different between the two
groups.
Regarding PPI treatment duration, Lee et al.(4) assigned patients
to treatment with PPI for 7 days (n = 26) or 28 days (n = 34) after
EMR. At 4 weeks after EMR, there were no significant differences
between the two groups in terms of ulcer reduction ratio or stage.
There are neither well-documented reports examining whether
treatment for post-ESD ulcers and peptic ulcers produce similar
outcomes nor those evaluating whether healing of post-ESD ulcers
is different from post-EMR ulcers. Therefore, we compared the
effects of H2RA and PPI on ulcer healing in patients with ESD-
induced ulcers. We also classified ESD-induced ulcers into 2
groups of less than 400 mm2 and at least 400 mm2 and compared
ulcer healing by size.
We compared the rate of decrease in ulcer size at 4 and 8 weeks
after treatment initiation. There were no significant differences
between the H2RA and PPI groups and ulcer healing rates were
similar in the two groups. Post-ESD ulcer sizes were examined
after stratifying ulcers into two ulcer size groups, less than
400 mm2 and at least 400 mm2 at baseline, and the analysis
indicated no significant difference in the rate of decrease in ulcer
size between the two groups at 4 and 8 weeks after the start of
treatment. Furthermore, most of the patients in both groups
showed cure at Week 8.
Kim et al.(13) reported that the safety and efficacy profiles of PPI
and a newly developed acid-pump antagonist are similar for the
treatment of ESD-induced ulcers. Kakushima et al.(14) indicated
that even larger post-ESD ulcers are potentially curable with PPI
treatment in 8 weeks. On the other hand, this study demonstrated
roxatidine acetate hydrochloride, a H2RA, to also be as effective
for post-ESD ulcers as PPIs (Fig. 5).
There are some reports(15,16) that the combination therapy of PPI
plus rebamipide, a mucosal-protective agent, promoted post-ESD
ulcers. In this study, we compared the safety and efficacy profiles
of H2RA and PPI. Roxatidine acetate hydrochloride, H2RA has an
acid secretion inhibitory effect and a gastric mucus-increasing
effect.(17,18) Thus, roxatidine was considered to have favorable
effects due to its pharmacological properties on healing of well-
differentiated gastric carcinoma in this study; severe atrophy of
the background mucosa and a possible decrease in gastric acid
secretary capacity, and even decreases in gastric mucus protective
factors, may all be contributory.
Bleeding is among the post-endoscopic therapy complications.
Conventional EMR procedures dissecting relatively small carci-
nomas in a short time were considered to be less affected by
electrocoagulation such that there would be no difference in post-
EMR bleeding between the H2RA and the PPI treatment groups.(3)
In contrast, ESD procedures using electrocautery applying an
electric current to the target lesion may result in severe damage to
the vessels, submucosal layer and the muscular layer on the floor
of the ulcer. The incidence of postoperative bleeding was 3 to 5%
with ESD procedures, higher than with EMR procedures. Isomoto
et al.(19) reviewed that bleeding during ESD can be managed
with coagulation forceps, and postoperative bleeding may be
reduced with routine use of the PPIs. In addition, Uedo et al.(20)
suggested, from the perspective of prophylaxis against bleeding,
that PPIs might inhibit postoperative bleeding significantly better
than H2RAs.
Specifically, since post-ESD bleeding was observed in 3.3%
of patients with tumors measuring lesser than 2 cm in diameter
and 31.6% of patients with tumors measuring 2 cm or more in
diameter; they reported that the tumor size was one of the signifi-
cant risk factors for post-ESD bleeding. We followed the proce-
dures reported by Uedo et al.(20) to treat any visible vessels and
adherent clots in the floor of the postoperative ulcer with hot
biopsy forceps in the soft coagulation mode at 80-W current.
Insufficient hemostasis was treated carefully with bigger hemo-
static forceps (Radial Jow 3 HOT Boston Scientific, Marlborough,
Natick, Massachusetts) or with a coagulation wave at a higher-
power setting (Forced Effect 2, 40W).
Consequently, no post-ESD bleeding was observed in 69 lesions
of patients receiving either H2RA or PPI treatment in this study
and the percent decrease of the ulcer size was at least 90% in both
groups at 8 weeks; there was no significant difference. Therefore,
prophylactic hemostasis was considered to be useful to prevent
post-ESD bleeding.
Takizawa et al.(21) also indicated that prophylactic coagulation
of exposed blood vessels in the ulcer floor is essential for preven-
tion of bleeding.
Kawano et al.(22) evaluated the possibility of reducing the dose
of PPI for the treatment of ESD-induced ulcers and concluded
that a reduced dose of PPI after 1 week of ESD was equivalent in
treatment performance to the standard dose and cheaper. However,
roxatidine acetate hydrochloride was considered to be a cost-
effective drug due to its lower price than a reduced dose of PPIs.
Meanwhile, even though PPIs are useful for the treatment of
peptic ulcers, interaction with clopidogrel used after coronary
artery stenting is currently acknowledged as a problem. Both
clopidogrel and PPIs are known to be metabolized by CYP2C19,
therefore, PPIs may decrease the level of active metabolite of
clopidogrel and attenuate the anti-platelet effect of clopidogrel.
Moreover, Ho et al.(23) assessed the adverse outcomes in 8205
patients taking clopidogrel with or without PPIs after hospitaliza-
tion for acute coronary syndrome, and reported that patients taking
Table 5. The rate of decrease in ulcer size (ulcers at least 400 mm2)
mean ± SD (95% CI)
2 sample t test (ns)
The mean size of 17 ulcers exceeding 400 mm2 was 804.8 ± 496.8 mm2 in
the H2RA group and the rate of decrease in size was 89.3 ± 10.7% at
Week 4 and 99.7 ± 1.0% at Week 8. The mean size of 20 large ulcers was
896.5 ± 533.4 mm2 in the PPI group and the rate of decrease in size was
85.6 ± 25.2% at Week 4 and 99.5 ± 1.4% at Week 8. There were no
significant differences between the two groups. H2RA, H2 receptor
antagonist; PPI, proton pump inhibitor.
Week 4 Week 8
H2RA 89.3 ± 10.7% 99.7 ± 1.0%
(n = 17) (84.2–94.4) (99.2–100)
PPI 85.6 ± 25.2% 99.5 ± 1.4%
(n = 20) (74.5–96.6) (98.9–100) J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 221
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clopidogrel with PPIs had a significantly higher risk of death or
rehospitalization for acute coronary syndrome compared with
patients taking clopidogrel without PPI.
In conclusion, this study demonstrated that post-ESD ulcers of
any size are potentially curable with either H2RA or PPI therapy in
Japan, with outcomes being equivalent at approximately 8 weeks.
H2RAs without effects on CYPs might be safer to treat post-ESD
than PPIs because of the potential of drug interactions following
concomitant administration of PPIs with other drugs.
Abbreviations
EMR endoscopic mucosal resection
ERHSE Endoscopic Resection with local injection of Hyper-
tonic Saline Epinephrine solution
ESD endoscopic submucosal dissection
H2RA H2 receptor antagonist
IT insulated tip
PPI proton pump inhibitor
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